T2 Biosystems to Participate in Singular Research Spring Select Web Call
May 24 2019 - 7:30AM
T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the development
of innovative diagnostic products for critical unmet needs in
healthcare, announced today that John McDonough, chief executive
officer, and John Sprague, chief financial officer, are scheduled
to participate in the Singular Research Spring Select Web Call on
Thursday, May 30, 2019 at 3:00 pm ET. In addition, the Company is
reiterating its 2019 guidance of a doubling of revenue and securing
70-80 T2Dx instrument contracts.
During the presentation, Mr. McDonough will provide an overview
of the Company and highlight some of the key attributes of the
Company’s technology:
- The T2Bacteria Panel covers 90% of the deadly ESKAPE bacteria –
those commonly resistant to broad spectrum antibiotics.1 When
combined with standard protocols that start patients on a broad
spectrum antibiotic the result is that approximately 90% of
patients may be delivered an effective therapy within 3 to 5 hours,
instead of days if treatment is solely dependent on
blood-culture-based, probability-driven therapy used broadly
today.2
- The species currently included in the T2Candida panel account
for >95% of invasive candidiasis.345 The rapid detection of
Candida enables physicians to provide targeted treatment quickly,
and research has shown this can reduce a positive sepsis patient's
length of stay in the hospital. In addition, a rapid negative
result can prevent unnecessary administration of antimicrobials,
further reducing costs and preventing or reducing antimicrobial
resistance.
- The T2Dx Instrument and associated T2Bacteria and T2Candida
Panels are the first and only FDA-cleared tests to identify
sepsis-causing bacteria and fungal pathogens directly from whole
blood, without the wait for blood culture. All other FDA-cleared
tests are blood-culture dependent and rely on that often lengthy
and inaccurate process, while many infections become more dangerous
with every passing hour.
The presentation will be webcast live and may be accessed by
visiting the Investors/Events & Presentations section of the
Company’s website at www.t2biosystems.com. A replay of the webcast
will be available shortly after the conclusion of the presentation
and will be archived on the Company's website for 90 days following
the presentation.
About Singular ResearchSingular Research aims
to be the most trusted supplier of independent, trusted,
single-source research on small-to-micro cap companies to the
small-to-medium sized Hedge Fund manager. The firm’s picks have
gained 299.3% since inception in 2004, compared with a gain of
116.4% for the Russell 2000 and 77.8% for the S&P 500 over the
same period. The Singular Research Spring Select Web Call features
their top growth and value ideas for total return in 2019.
About T2 Biosystems T2 Biosystems, a
leader in the development and commercialization of innovative
medical diagnostic products for critical unmet needs in healthcare,
is dedicated to improving patient care and reducing the cost of
care by helping clinicians effectively treat patients faster than
ever before. T2 Biosystems’ products include the T2Dx® Instrument,
T2Candida® Panel, and T2Bacteria® Panel and are powered by the
proprietary T2 Magnetic Resonance (T2MR®) technology. T2 Biosystems
has an active pipeline of future products, including products for
the detection of additional species and antibiotic resistance
markers of sepsis pathogens, and tests for Lyme disease.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. All statements contained in this press release that do not
relate to matters of historical fact should be considered
forward-looking statements, including, without limitation,
statements regarding additional patients, timing of testing
patients, anticipated product benefits, strategic priorities,
product expansion or opportunities, growth expectations or targets,
timing of FDA filings or clearances and anticipated operating
expenses, as well as statements that include the words “expect,”
“intend,” “plan”, “believe”, “project”, “forecast”, “estimate,”
“may,” “should,” “anticipate,” and similar statements of a future
or forward looking nature. These forward-looking statements are
based on management's current expectations. These statements are
neither promises nor guarantees, but involve known and unknown
risks, uncertainties and other important factors that may cause
actual results, performance or achievements to be materially
different from any future results, performance or achievements
expressed or implied by the forward-looking statements, including,
but not limited to, (i) any inability to (a) realize anticipated
benefits from commitments, contracts or products; (b) successfully
execute strategic priorities; (c) bring products to market; (d)
expand product usage or adoption; (e) obtain customer
testimonials; (f) accurately predict growth assumptions; (g)
realize anticipated revenues; (h) incur expected levels of
operating expenses; or (i) increase the number of high-risk
patients at customer facilities; (ii) failure of early data to
predict eventual outcomes; (iii) failure to make or obtain
anticipated FDA filings or clearances within expected time frames
or at all; or (iv) the factors discussed under Item 1A. "Risk
Factors" in the company's Annual Report on Form 10-K for the year
ended December 31, 2018, filed with the U.S. Securities and
Exchange Commission, or SEC, on March 14, 2019, and other filings
the company makes with the SEC from time to time. These and
other important factors could cause actual results to differ
materially from those indicated by the forward-looking statements
made in this press release. Any such forward-looking statements
represent management's estimates as of the date of this press
release. While the company may elect to update such forward-looking
statements at some point in the future, unless required by law, it
disclaims any obligation to do so, even if subsequent events cause
its views to change. Thus, no one should assume that the Company’s
silence over time means that actual events are bearing out as
expressed or implied in such forward-looking statements.
These forward-looking statements should not be relied upon as
representing the company's views as of any date subsequent to the
date of this press release.
1 Karlowskey, J. A., Jones, M. E., Draghi, D. C. et al (2004)
Prevalence and antimicrobial susceptibilities of bacteria isolated
from blood cultures of hospitalized patients in the United States
in 2002. Annals of Clinical Microbiology and Antimicrobials 2004
3:7.2 Kumar, A., Ellis, P., Arabi, Y., et al. (2009). Initiation of
inappropriate antimicrobial therapy results in a fivefold reduction
of survival in human septic shock. CHEST Journal, 136(5),
1237-1248.3 Clancy, C. J., Pappas, P. G., Vazquez, J. et al.
(2018). Detecting Infections Rapidly and Easily for
Candidemia Trial, Part 2 (DIRECT2): A Prospective, Multicenter
Study of the T2Candida Panel. Clinical Infectious Diseases, 66,
1678-1686.4 Pfaller MA, Moet GJ, Messer SA et al. (2011) Candida
bloodstream infections: comparison of species distributions and
antifungal resistance patterns in community-onset and nosocomial
isolates in the SENTRY Antimicrobial Surveillance Program,
2008–2009. Antimicrob. Agents Chemother. 55, 561–566.5 Pfaller MA,
Neofytos D, Diekema D et al. (2012) Epidemiology and outcomes of
candidemia in 3648 patients: data from the Prospective Antifungal
Therapy (PATH Alliance(R)) Registry, 2004–2008. Diagn. Microbiol.
Infect. Dis. 74, 323–331.
Media Contact:Gina Kent, Vault
Communicationsgkent@vaultcommunications.com610-455-2763
Investor Contact: Zack Kubow, W2O Group
zkubow@w2ogroup.com 415-658-6436
T2 Biosystems (NASDAQ:TTOO)
Historical Stock Chart
From Mar 2024 to Apr 2024
T2 Biosystems (NASDAQ:TTOO)
Historical Stock Chart
From Apr 2023 to Apr 2024